A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors
Latest Information Update: 21 Jun 2025
At a glance
- Drugs SSGJ-705 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 20 Jun 2025 New trial record